PA5-27451

antibody from Invitrogen Antibodies

Targeting: CRABP2 CRABP-II

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-27451

Provider

Invitrogen Antibodies

Product name

CRABP2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: A549, HepG2, mouse brain, mouse fetal brain, rat brain. Predicted reactivity: Mouse (94%), Rat (94%), Xenopus laevis (89%), Pig (95%), Rhesus Monkey (100%), Bovine (97%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue.

Chen W, Dong J, Plate L, Mortenson DE, Brighty GJ, Li S, Liu Y, Galmozzi A, Lee PS, Hulce JJ, Cravatt BF, Saez E, Powers ET, Wilson IA, Sharpless KB, Kelly JW
Journal of the American Chemical Society 2016 Jun 15;138(23):7353-64

---

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M
Nature communications 2016 Aug 26;7:12645

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

CRABP2 Polyclonal Antibody detects CRABP2 protein at cytoplasm and nucleus by immunofluorescent analysis. Sample: HCT116 cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: CRABP2 protein stained by CRABP2 Polyclonal Antibody (Product # PA5-27451) diluted at 1:500. Blue: Hoechst 33342 staining.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 Integrative analysis of HGSOC tissue and cell line proteomes. ( a ) Proteomic clustering of eight HGSOC tissue specimens. PCA was performed on the ovarian tumour specimens ( n =8) based on the proteomic profiles to evaluate inter-patient heterogeneity and intra-patient homogeneity. Component 1 and component 2 account for 51.5% of the total data variation. ( b ) PCA clustering of cell lines ( n =30), FTEC ( n =3) and HGSOC tissue proteomes ( n =8). Groups I (green), II (blue) and III (red) are as defined in Fig. 3 . The juxtaposition of the IOSE cell lines, red circles outlined in black, relative to the rest of the group III cell lines is indicated. Component 1 and component 2 account for 28.1% of the total data variation. ( c ) PCA segregation and clustering of all samples based on the 67-protein signature. The juxtaposition of the IOSE cell lines, red circles outlined in black, relative to the rest of the group III cell lines is indicated. Component 1 and component 2 account for 54.8% of the total data variation. The dendrogram below the PCA summarizes the hierarchical clustering analysis of all samples based on the 67-protein signature. Two main clusters were obtained based on this signature (detailed in Supplementary Fig. 3c ). ( d ) Relative levels of the 67 proteins used for PCA clustering in c . Relative protein levels (MaxLFQ intensities, log2) are depicted by circle size. Colours indicate protein sequence coverage per sample. MSLN is depicted twice, represent